Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cocrystal Pharma's enterprise value is €9.85 Mil.
Cocrystal Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-7.45 Mil. Therefore, Cocrystal Pharma's EV-to-EBITDA for today is -1.32.
The historical rank and industry rank for Cocrystal Pharma's EV-to-EBITDA or its related term are showing as below:
FRA:8CC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.02 Med: -0.52 Max: 4.61
Current: -1.31
During the past 13 years, the highest EV-to-EBITDA of Cocrystal Pharma was 4.61. The lowest was -12.02. And the median was -0.52.
FRA:8CC's EV-to-EBITDA is ranked worse than 100% of 409
companies
in the Biotechnology industry
Industry Median: 12.99
vs FRA:8CC: -1.31
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cocrystal Pharma's PE Ratio (TTM) for today is calculated as:
Cocrystal Pharma's share price for today is €0.865.
Cocrystal Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.627.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cocrystal Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8CC vs ANEB, BCDA, PHIO: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Cocrystal Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cocrystal Pharma EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cocrystal Pharma's EV-to-EBITDA falls into.
Cocrystal Pharma's current Enterprise Value is €9.85 Mil.
Cocrystal Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cocrystal Pharma (FRA:8CC) has a EV-to-EBITDA of -1.32 as of Aug. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cocrystal Pharma. According to the industry distribution chart, Cocrystal Pharma ranks #999999 out of 409 companies in the Biotechnology industry.
Is Cocrystal Pharma's EV-to-EBITDA too high?
Cocrystal Pharma's current EV-to-EBITDA is -1.32. Based on the distribution chart, Cocrystal Pharma ranks #999999 out of 409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cocrystal Pharma has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cocrystal Pharma's EV-to-EBITDA compare to ANEB and BCDA?
According to the Biotechnology industry distribution chart, Cocrystal Pharma ranks #999999 out of 409 companies for EV-to-EBITDA. This places Cocrystal Pharma in the lower half of its industry. The industry median EV-to-EBITDA is 12.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.99, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cocrystal Pharma. For the Biotechnology industry, the median EV-to-EBITDA is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cocrystal Pharma's current EV-to-EBITDA is -1.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cocrystal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Cocrystal Pharma (FRA:8CC) is currently considered Possible Value Trap. The stock's GF Value™ is €2.43, compared to a current price of €0.87 — trading 64.4% below its estimated fair value. The current EV-to-EBITDA is -1.32. Cocrystal Pharma's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cocrystal Pharma (FRA:8CC), the current EV-to-EBITDA is -1.32 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cocrystal Pharma (FRA:8CC) Overvalued in 2026?
Based on GuruFocus' analysis, Cocrystal Pharma stock appears to be undervalued.
The current stock price of €0.87 is trading 64.4% below its estimated GF Value™ of €2.43.
GuruFocus considers Cocrystal Pharma to be Possible Value Trap.
Key valuation signals for FRA:8CC:
EV-to-EBITDA: -1.32
GF Value™: €2.43 vs. price of €0.87 (64.4% below fair value)
No single metric tells the full story. See the FRA:8CC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
41GF Score
Get the complete analysis for FRA:8CC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8CC has been successfully added to your 
